Novavax Vaccine Was Successful, Company’s Stocks Soared

The Novavax vaccine was successful, the company's stocks soared. US vaccine manufacturer Novavax recorded a 90 percent success rate.

The coronavirus vaccine developed by the US vaccine manufacturer Novavax created 90 percent immunity in the third phase clinical trials in the USA and Mexico. It was reported that the vaccine, which was reported to have no serious side effects, was tested with approximately 30 thousand subjects over the age of 18. In the trial in which the vaccine formula was applied to two thirds of the subjects and the fake formula called "placebo" was applied to one third, the virus was detected in 77 people, 14 of whom were in the experimental group in which the vaccine was administered. The company reported that it aims to produce 100 million doses of Covid-19 vaccine per month by September.

Company's Stocks Gained Value

Stocks of Novavax (NASDAQ:NVAX) gained more than 6 percent after the news. If approved, the Novavax vaccine will be among Pfizer/BioNTech (NYSE:PFE) (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and Johnson&Johnson (NYSE:JNJ) which have received emergency use approval in the US.